NCT07490626 2026-03-27
Paracentesis
University of Utah
Phase NA Not yet recruiting
Clinical Trials
9 trialsNCT07397819 2026-02-09
Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy
Sun Yat-sen University
Phase 1/2 Recruiting
NCT06266091 2025-07-20
Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody
Wuhan YZY Biopharma Co., Ltd.
Phase 2 Completed
NCT06432296 2025-07-20
Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody
Wuhan YZY Biopharma Co., Ltd.
Phase 3 Active not recruiting
NCT07007988 2025-06-06
SIM0388-101
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06433869 2024-05-30
The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites
Sun Yat-sen University
Phase 2 Recruiting
NCT06200376 2024-01-11
A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer
West China Hospital
Phase 1 Unknown
NCT05745233 2023-08-24
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
China Medical University Hospital
Phase NA Enrolling by invitation
NCT05501340 2022-08-15
PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites
Second Affiliated Hospital of Soochow University
Phase 1/2 Unknown